Logo image of EWL.DE

EDWARDS LIFESCIENCES CORP (EWL.DE) Stock Fundamental Analysis

FRA:EWL - Deutsche Boerse Ag - US28176E1082 - Common Stock - Currency: EUR

64.93  -0.55 (-0.84%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to EWL. EWL was compared to 59 industry peers in the Health Care Equipment & Supplies industry. EWL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EWL is valied quite expensively at the moment, while it does show a decent growth rate. These ratings could make EWL a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

EWL had positive earnings in the past year.
In the past year EWL had a positive cash flow from operations.
In the past 5 years EWL has always been profitable.
EWL had a positive operating cash flow in each of the past 5 years.
EWL.DE Yearly Net Income VS EBIT VS OCF VS FCFEWL.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

1.2 Ratios

EWL has a better Return On Assets (32.10%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 41.28%, EWL belongs to the best of the industry, outperforming 98.31% of the companies in the same industry.
EWL has a better Return On Invested Capital (9.29%) than 77.97% of its industry peers.
The Average Return On Invested Capital over the past 3 years for EWL is above the industry average of 8.57%.
Industry RankSector Rank
ROA 32.1%
ROE 41.28%
ROIC 9.29%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)12.44%
ROIC(5y)13.58%
EWL.DE Yearly ROA, ROE, ROICEWL.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

With an excellent Profit Margin value of 75.48%, EWL belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
EWL's Profit Margin has improved in the last couple of years.
The Operating Margin of EWL (27.71%) is better than 94.92% of its industry peers.
EWL's Operating Margin has been stable in the last couple of years.
EWL's Gross Margin of 79.38% is amongst the best of the industry. EWL outperforms 86.44% of its industry peers.
In the last couple of years the Gross Margin of EWL has remained more or less at the same level.
Industry RankSector Rank
OM 27.71%
PM (TTM) 75.48%
GM 79.38%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
EWL.DE Yearly Profit, Operating, Gross MarginsEWL.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

10

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EWL is creating some value.
EWL has less shares outstanding than it did 1 year ago.
EWL has less shares outstanding than it did 5 years ago.
The debt/assets ratio for EWL has been reduced compared to a year ago.
EWL.DE Yearly Shares OutstandingEWL.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
EWL.DE Yearly Total Debt VS Total AssetsEWL.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

EWL has an Altman-Z score of 11.85. This indicates that EWL is financially healthy and has little risk of bankruptcy at the moment.
EWL has a better Altman-Z score (11.85) than 94.92% of its industry peers.
The Debt to FCF ratio of EWL is 0.96, which is an excellent value as it means it would take EWL, only 0.96 years of fcf income to pay off all of its debts.
EWL has a better Debt to FCF ratio (0.96) than 91.53% of its industry peers.
EWL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of EWL (0.06) is better than 91.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.96
Altman-Z 11.85
ROIC/WACC1.04
WACC8.95%
EWL.DE Yearly LT Debt VS Equity VS FCFEWL.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

EWL has a Current Ratio of 4.45. This indicates that EWL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of EWL (4.45) is better than 89.83% of its industry peers.
EWL has a Quick Ratio of 3.66. This indicates that EWL is financially healthy and has no problem in meeting its short term obligations.
EWL's Quick ratio of 3.66 is amongst the best of the industry. EWL outperforms 91.53% of its industry peers.
Industry RankSector Rank
Current Ratio 4.45
Quick Ratio 3.66
EWL.DE Yearly Current Assets VS Current LiabilitesEWL.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

5

3. Growth

3.1 Past

EWL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.96%.
The Earnings Per Share has been growing slightly by 7.13% on average over the past years.
EWL shows a decrease in Revenue. In the last year, the revenue decreased by -6.00%.
EWL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.58% yearly.
EPS 1Y (TTM)1.96%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%-3.03%
Revenue 1Y (TTM)-6%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%-11.61%

3.2 Future

The Earnings Per Share is expected to grow by 9.05% on average over the next years. This is quite good.
EWL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.25% yearly.
EPS Next Y-2.56%
EPS Next 2Y4.27%
EPS Next 3Y6.72%
EPS Next 5Y9.05%
Revenue Next Year2.36%
Revenue Next 2Y5.89%
Revenue Next 3Y7.36%
Revenue Next 5Y8.25%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EWL.DE Yearly Revenue VS EstimatesEWL.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
EWL.DE Yearly EPS VS EstimatesEWL.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 28.86 indicates a quite expensive valuation of EWL.
Based on the Price/Earnings ratio, EWL is valued a bit cheaper than 66.10% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.57. EWL is around the same levels.
EWL is valuated quite expensively with a Price/Forward Earnings ratio of 26.38.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EWL is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.41, EWL is valued at the same level.
Industry RankSector Rank
PE 28.86
Fwd PE 26.38
EWL.DE Price Earnings VS Forward Price EarningsEWL.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

EWL's Enterprise Value to EBITDA is on the same level as the industry average.
EWL's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 70.75
EV/EBITDA 23.71
EWL.DE Per share dataEWL.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

EWL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)4.05
EPS Next 2Y4.27%
EPS Next 3Y6.72%

0

5. Dividend

5.1 Amount

EWL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

EDWARDS LIFESCIENCES CORP

FRA:EWL (6/16/2025, 7:00:00 PM)

64.93

-0.55 (-0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-23 2025-04-23/amc
Earnings (Next)07-22 2025-07-22/amc
Inst Owners89.36%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap38.09B
Analysts74.15
Price Target72.82 (12.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.76%
Min EPS beat(2)3.4%
Max EPS beat(2)4.11%
EPS beat(4)3
Avg EPS beat(4)1.75%
Min EPS beat(4)-2.08%
Max EPS beat(4)4.11%
EPS beat(8)3
Avg EPS beat(8)-0.01%
EPS beat(12)4
Avg EPS beat(12)-0.74%
EPS beat(16)6
Avg EPS beat(16)-0.44%
Revenue beat(2)0
Avg Revenue beat(2)-1.49%
Min Revenue beat(2)-2.1%
Max Revenue beat(2)-0.87%
Revenue beat(4)0
Avg Revenue beat(4)-5.21%
Min Revenue beat(4)-13.79%
Max Revenue beat(4)-0.87%
Revenue beat(8)0
Avg Revenue beat(8)-3.29%
Revenue beat(12)1
Avg Revenue beat(12)-2.9%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)0.35%
PT rev (3m)-6.01%
EPS NQ rev (1m)0.15%
EPS NQ rev (3m)0.82%
EPS NY rev (1m)0%
EPS NY rev (3m)1.1%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)1.5%
Valuation
Industry RankSector Rank
PE 28.86
Fwd PE 26.38
P/S 7.96
P/FCF 70.75
P/OCF 50.31
P/B 4.35
P/tB 6.14
EV/EBITDA 23.71
EPS(TTM)2.25
EY3.47%
EPS(NY)2.46
Fwd EY3.79%
FCF(TTM)0.92
FCFY1.41%
OCF(TTM)1.29
OCFY1.99%
SpS8.16
BVpS14.92
TBVpS10.57
PEG (NY)N/A
PEG (5Y)4.05
Profitability
Industry RankSector Rank
ROA 32.1%
ROE 41.28%
ROCE 13.2%
ROIC 9.29%
ROICexc 13.98%
ROICexgc 22.62%
OM 27.71%
PM (TTM) 75.48%
GM 79.38%
FCFM 11.25%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)12.44%
ROIC(5y)13.58%
ROICexc(3y)16.13%
ROICexc(5y)17.4%
ROICexgc(3y)22.87%
ROICexgc(5y)24.4%
ROCE(3y)17.66%
ROCE(5y)19.29%
ROICexcg growth 3Y-5.47%
ROICexcg growth 5Y-8.01%
ROICexc growth 3Y-11.82%
ROICexc growth 5Y-8.6%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
F-Score7
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.96
Debt/EBITDA 0.35
Cap/Depr 165.1%
Cap/Sales 4.57%
Interest Coverage 250
Cash Conversion 51.91%
Profit Quality 14.9%
Current Ratio 4.45
Quick Ratio 3.66
Altman-Z 11.85
F-Score7
WACC8.95%
ROIC/WACC1.04
Cap/Depr(3y)185.14%
Cap/Depr(5y)236.01%
Cap/Sales(3y)5.48%
Cap/Sales(5y)6.41%
Profit Quality(3y)37.92%
Profit Quality(5y)57.13%
High Growth Momentum
Growth
EPS 1Y (TTM)1.96%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%-3.03%
EPS Next Y-2.56%
EPS Next 2Y4.27%
EPS Next 3Y6.72%
EPS Next 5Y9.05%
Revenue 1Y (TTM)-6%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%-11.61%
Revenue Next Year2.36%
Revenue Next 2Y5.89%
Revenue Next 3Y7.36%
Revenue Next 5Y8.25%
EBIT growth 1Y-8.81%
EBIT growth 3Y-4.72%
EBIT growth 5Y3.49%
EBIT Next Year8.84%
EBIT Next 3Y11%
EBIT Next 5Y11.13%
FCF growth 1Y-36.77%
FCF growth 3Y-42.99%
FCF growth 5Y-22.01%
OCF growth 1Y-29.28%
OCF growth 3Y-32.1%
OCF growth 5Y-14.39%